The role of feeding habits in the management of inflammatory bowel diseases


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

For patients with ulcerative colitis (UC) or Crohn's disease (CD), the choice of food is considered one of the priority tasks. As a rule, they are advised to avoid spicy, fatty, fried foods, reduce the consumption of fruits and vegetables and enrich the diet with foods containing protein. The current reality of the management of patients with inflammatory bowel diseases (IBDs) is that doctors, mainly due to lack of visiting time, as well as limited evidence in the field of dietary recommendations, do not give them sufficient information on this important issue that determines the quality of life. Over the past few years, we have seen a renewed interest in studying the diet, not only as a cause of UC and CD, but also in treatment regimens as an addition to the necessary drugs. This is mainly due to a deeper understanding of the integral role of the microbiome in the pathogenesis of IBDs and how diet can affect the biodiversity and functionality of the intestinal microbiota. In this regard, we found it useful to conduct a comparative analysis of existing diets for patients suffering from IBDs. A literature search was conducted on PubMed and Google Scholar using the keywords “ulcerative colitis", “Crohn's disease," “colonic microbiota", and “diet". We have focused on clinical trials conducted over the past years, and present an overview of their effectiveness to general practitioners and gastroenterologists for use in daily practice.

Full Text

Restricted Access

About the authors

Galiya R. Bikbavova

Omsk State Medical University

Email: galiya1976@mail.ru
Cand. Sci. (Med.), Associate Professor at the Department of Hospital Therapy and Endocrinology Omsk, Russia

M. A Livzan

Omsk State Medical University

Omsk, Russia

T. V Tretyakova

Regional Clinical Hospital

Omsk, Russia

T. L Lazeeva

Regional Clinical Hospital

Omsk, Russia

A. A Zastavnaya

Omsk State Medical University

Omsk, Russia

References

  1. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. Hastroenterol. Hepatol. 2020;5(1):17-30. Doi: https://doi.org/10.1016/S2468-1253(19)30333-4.
  2. Shouval D., Rufo P. The role of environmental factors in the pathogenesis of inflammatory bowel diseases: a review. JAMA. Pediatr. 2017;171:999-1005. Doi: https://doi.org/10.1001/ jamapediatrics.2017.2571.
  3. Yatsunenko T., Rey F., Manary M., et al. Human gut microbiome viewed across age and geography. Nature. 2012;486:222e7. Doi: 10.1038/ nature11053.
  4. Kaplan G. The global burden of IBD: From 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720-27. Doi: 10.1038/ nrgast_ro.2015.150.
  5. Бикбавова Г.Р., Ливзан М.А., Совалкин В.И. и др. Влияние особенностей современного образа жизни на возникновение язвенного колита. Архив внутренней медицины. 2019;3:188-93.
  6. Racine A., Carbonnel F., Chan S.S.M., et al. Dietary patterns and risk of inflammatory bowel disease in Europe: results from the EPIC study. Inflamm Bowel Dis. 2016;22:345-54. Doi: https://doi. org/10.1097/mib.0000000000000638.
  7. Gottschall E. Breaking the vicious Cycle: intestinal health through diet. Baltimore (Ontario, Canada): Kirkton Press, 1994.
  8. Obih C., Wahbeh G., Lee D., et al. Specific carbohydrate diet for pediatric inflammatory bowel disease in clinical practice within an academic IBD center. Nutrition. 2016;32:418-25. Doi: https:// doi.org/10.1016/j.nut.2015.08.025.
  9. Burgis J.C., Nguyen K., Park K.T, Cox K. Response to strict and liberalized specific carbohydrate diet in pediatric Crohn's disease. W J Gastroenterol. 2016;22:2111-17. Doi: https://doi. org/10.3748/wjg.v22.i6.2111.
  10. Cohen S.A., Gold B.D., Oliva S., et al. Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. J Pediatr GastroenterolNutr. 2014;59:516-21. Doi:https:// doi.org/10.1097/mpg.0000000000000449.
  11. Suskind D.L., Wahbeh G., Gregory N., et al. Nutritional therapy in pediatric Crohn disease: the specific carbohydrate diet. J Pediatr Gastroenterol Nutr. 2014;58:87-91. Doi: https://doi. org/10.1097/mpg.0000000000000103.
  12. Suskind D.L., Wahbeh G., Cohen S.A., et al. Patients perceive clinical benefit with the specific carbohydrate diet for inflammatory bowel disease. Dig Dis Sci. 2016;61:3255e60. Doi: https://doi. org/10.1007/s10620-016-4307-y.
  13. Aleksandrova K., Romero-Mosquera B., Hernandez V. Diet. Gut microbiome and epigenetics: Emerging links with inflammatory bowel diseases and prospects for management and prevention. Nutrients. 2017;9:E962. Doi: https://doi. org/10.3390/nu9090962
  14. Morrison D.J., Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut. Microbes. 2016;7:189-200. Doi: https://doi.org/10.1080 /19490976.2015.1134082.
  15. Olendzki B.C., Silverstein T.D., Persuitte G.M., et al. An anti-inflammatory diet as treatment for inflammatory bowel disease: a case series report. Nutr J. 2014;13:5. Doi: https://doi. org/10.1186/1475-2891-13-5.
  16. Fernandez-Banares F, Hinojosa J., Sanchez-Lombrana J.L., et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol. 1999;94:427e33. Doi: https:// doi.org/10.1016/s0002-9270(98)00753-9.
  17. Voegtlin W.L. The stone age diet: based on in-depth studies of human ecology and the diet of man. N.-Y, Washington: Vantage Press, 1975.
  18. Konner M., Eaton S.B. Paleolithic nutrition: twenty-five years later. Nutr Clin Pract. 2010;25:594e602. Doi: https://doi. org/10.1177/0884533610385702.
  19. Konijeti G.G., Kim N., Lewis J.D., et al. Efficacy of the autoimmune protocol diet for inflammatory bowel disease. Inflamm. Bowel Dis. 2017;23:2054-60. Doi: https://doi. org/10.1097/mib.0000000000001221.
  20. Levine A., Sigall Boneh R., Wine E. Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases. Gut. 2018;67(9):1726-38. Doi: https://doi.org/10.1136/gutjnl-2017-315866.
  21. Cohen-Dolev N., Sladek M., Hussey S., et al. Differences in outcomes over time with exclusive enteral nutrition compared with steroids in children with mild to moderate Crohn's disease: results from the GROWTH CD study. J Crohns Colitis. 2018;12:306-12. Doi: https://doi.org/10.1093/ ecco-jcc/jjx150.
  22. Grover Z., Burgess C., Muir R., et al. Early mucosal healing with exclusive enteral nutrition is associated with improved outcomes in newly diagnosed children with luminal Crohn's disease. J Crohns Colitis. 2016;10:1159-64. Doi: https:// doi.org/10.1093/ecco-jcc/jjw075.
  23. Wall C.L., Gearry R.B., Day A.S. Treatment of active Crohn's disease with exclusive and partial enteral nutrition: a pilot study in adults. Inflamm Intest Dis. 2018;2:219-27. Doi: https://doi. org/10.1159/000489630.
  24. Ruemmele F.M., Veres G., Kolho K.L., et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014;8:1179-207. Doi: https:// doi.org/10.1016/s1873-9946(14)50148-1.
  25. Hu D., Ren J., Wang G., et al. Exclusive enteral nutritional therapy can relieve inflammatory bowel stricture in Crohn's disease. J Clin Gastroenterol. 2014;48:790-95. Doi: https://doi.org/10.1097/ mcg.0000000000000041.
  26. Heerasing N., Thompson B., Hendy P, et al. Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for adults with Crohn's disease. Aliment Pharmacol Ther. 2017;45:660-69. Doi: https://doi.org/10.1111/ apt.13934.
  27. Sigall-Boneh R., Pfeffer-Gik T., Segal I., et al. Partial enteral nutrition with a Crohn's disease exclusion diet is effective for induction of remission in children and young adults with Crohn's disease. Inflamm Bowel Dis. 2014;20:1353-60. Doi: https://doi. org/10.1097/mib.0000000000000110.
  28. Heerasing N., Thompson B., Hendy P, et al. Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for adults with Crohn's disease. Aliment Pharmacol Ther. 2017;45:660-69. Doi: https://doi.org/10.1111/ apt.13934.
  29. Prince A.C., Myers C.E., Joyce T., et al. Fermentable carbohydrate restriction (low FODMAP diet) in clinical practice improves functional gastrointestinal symptoms in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(5):1129-36. Doi: https://doi. org/10.1097/mib.0000000000000708.
  30. Halmos E.P., Christophersen C.T., Bird A.R., et al. Consistent prebiotic effect on gut microbiota with altered FODMAP intake in patients with Crohn's disease: a randomised, controlled cross-over trial of well-defined diets. Clin Transl Gastroenterol. 2016;7:e164. Doi: https://doi.org/10.1038/ ctg.2016.22.
  31. Zhan Y-L., Zhan Y-A., Dai S-X. Is a low FODMAP diet beneficial for patients with inflammatory bowel disease? A meta-analysis and systematic review. Clin Nutr. 2018;37:123-29. Doi: https:// doi.org/10.1016/j.clnu.2017.05.019.
  32. Lang A., Salomon N., Wu J.C.Y, et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 2015;13:1444-9.e1. Doi: https://doi. org/10.1016/j.cgh.2015.02.019.
  33. Banerjee R., Penmetsa A., Medaboina K., et al. Novel bio-enhanced curcumin with mesalamine for induction of remission in mild to moderate ulcerative colitis. Gastroenterol. 2017;152:S587. Doi: https://doi.org/10.1016/s0016-5085(17)32111-x.
  34. Grammatikopoulou M.G., Gkiouras K., Theodoridis X., et al. Oral adjuvant curcumin therapy for attaining clinical remission in ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2018;10(11). Doi: https://doi.org/10.3390/nu10111737.
  35. Ворслов Л.О., Тюзиков И.А., Калинченко С.Ю. и др. Квартет здоровья - новая концепция современной профилактической медицины. Лечащий врач. 2015;12:28-33.
  36. Kotwal S., Jun M., Sullivan D., et al. Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2012;5(6):808-18. Doi: https://doi. org/10.1161/circoutcomes.112.966168.
  37. Ito Z., Uchiyama K., Odahara S., et al. Fatty Acids as Useful Serological Markers for Crohn's Disease. Dig Dis. 2018;36(3):209-17. Doi: https://doi. org/10.1159/000485096.
  38. Novak T.E., Babcock T.A., Jho D.H., et al. NF-kappa B inhibition by Omega -3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol. 2003;284:L84-9. Doi: https://doi.org/10.1152/ ajplung.00077.2002.
  39. Marion-Letellier R., Savoye G., Beck PL., et al. Polyunsaturated fatty acids in inflammatory bowel diseases: a reappraisal of effects and therapeutic approaches. Inflamm Bowel Dis. 2013;19(3):650-61. Doi: https://doi. org/10.1097/mib.0b013e3182810122.
  40. Zhou Y.Q., Xu R.Y., Wan Y.P The role of dietary factors in inflammatory bowel diseases: New perspectives. J Dig Dis. 2019;20(1):11-7. Doi: https://doi.org/10.1111/1751-2980.12686.
  41. Loeschke K., Ueberschaer B., Pietsch A., et al. N-3 fatty acids only delay early relapse of ulcerative colitis in remission. Dig Dis Sci. 1996;41:2087-94. Doi: https://doi.org/10.1007/bf02093614.
  42. Middleton S.J., Naylor S., Woolner J., Hunter J.O. A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. Aliment Pharmacol Ther. 2002;16:1131-35. Doi: https://doi.org/10.1046/j.1365- 2036.2002.01286.x.
  43. Cabré E., Manosa M., Gassull M.A. Omega-3 fatty acids and inflammatory bowel diseases - a systematic review. Br J Nutr. 2012;107(Suppl. 2):S240-52. Doi: https://doi.org/10.1017/ s0007114512001626.
  44. Feagan B.G., Sandborn W.J., Mittmann U., et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials. JAMA. 2008;299:1690-97. Doi: https://doi.org/10.1001/jama.299.14.1690.
  45. Ananthakrishnan A.N., Khalili H., Higuchi L.M., et al. Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterol. 2012;142:482-89. Doi: https:// doi.org/10.1053/j.gastro.2011.11.040.
  46. Li J., Chen N., Wang D., et al. Efficacy of vitamin D in treatment of inflammatory bowel disease: a metaanalysis. Med. 2018;97:e12662. Doi: https://doi. org/10.1097/md.0000000000012662.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies